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A B S T R A C T
Background and purpose: Approximately 20–25% of the patients with hypertrophic cardiomyopathy
(HCM) develop atrial ﬁbrillation (AF) during the clinical course of the disease, a percentage signiﬁcantly
larger than that of the general population. The purpose of the present study was to report on the
procedural results of patients with AF and either primary or secondary left ventricular hypertrophy
(LVH).
Methods and subjects: Twenty-two consecutive HCM patients (55% male, mean age 57  8 years) with
symptomatic AF, having undergone AF ablation procedures between September 2009 and July 2012 were
compared with respect to procedural outcome and follow-up characteristics with 22 matched controls with
secondary cardiac hypertrophy (64% male, 63  10 years) from our prospective AF catheter ablation registry.
Results and conclusion: Radiofrequency catheter ablation (RFCA) was successful in restoring long-term
sinus rhythm in patients with LVH due to HCM and due to secondary etiology. However, patients with
HCM needed more RFCA procedures and frequently additional antiarrhythmic drug therapy in order to
maintain sinus rhythm.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM) is the most common
genetically determined cardiomyopathy, with a prevalence of
0.2% in the general population. Approximately 20–25% of the
patients with HCM will eventually develop atrial ﬁbrillation (AF)
during the clinical course of the disease, a percentage signiﬁ-
cantly larger than that of the general population [1–5]. AF is a
major factor of morbidity and mortality in HCM, causing
ischemic strokes and systemic embolisms, exacerbation of
symptoms of heart failure, pulmonary congestion and edema,* Corresponding author at: Department of Electrophysiology, University of
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsdeterioration of the already compromised diastolic ﬁlling of the
left ventricle, as well as provoking appropriate and inappropriate
discharges in patients with implantable cardioverter-deﬁbrilla-
tors (ICDs), dramatically affecting their quality of life [1,6–10]. As
a consequence, recent AF treatment guidelines favor an aggres-
sive approach to both rhythm control and stroke prevention in
patients with HCM [11].
In this context, catheter ablation of AF is recommended for
patients with drug refractory AF and for patients with antiar-
rhythmic agent (AAA) intolerance [11]. Catheter ablation has
consistently shown satisfactory results regarding symptoms relief
and survival free of arrhythmia for both paroxysmal and persistent
AF in the general population [11]. It is unclear whether patients
with HCM achieve the same results. Most of the data on AF ablation
in patients with HCM are derived from cohorts with small numbers
of patients, and success rates vary between 49% and 100%
[13,17,23, Table3]. reserved.
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failure and is associated with an adverse outcome in HCM patients
[1], maintenance of sinus rhythm is highly desirable. This study
compared the efﬁcacy and clinical outcomes between patients
with LVH due to HCM and patients with secondary cardiac
hypertrophy due to hypertensive cardiomyopathy.
Materials and methods
Population
A total of 22 consecutive HCM patients (55% male, mean age
57  8 years) with highly symptomatic AF, having undergone AF
ablation procedures between September 2009 and July 2012 were
compared with respect to procedural outcome and follow-up
characteristics with 22 matched controls with secondary cardiac
hypertrophy (64% male, 63  10 years) from our prospective AF
catheter ablation registry. Table 1 displays the baseline character-
istics. Matched parameters included LV hypertrophy, systolic LV
function, and AF type. Diagnosis of HCM was based on two-
dimensional echocardiographic evidence of a hypertrophied, non-
dilated left ventricle (maximum wall thickness 15 mm) and/or
relevant outﬂow tract obstruction, in the absence of any other cardiac
or systemic condition capable of producing such magnitude of
hypertrophy [14]. Diagnosis of secondary cardiac hypertrophy was
based on two-dimensional echocardiographic evidence of an
interventricular septum 14 mm and evidence of a causative
condition. Hypertensive disease was diagnosed in 22 out of 22
patients (100%) with secondary cardiac hypertrophy. If arterial
hypertension was also found in patients with HCM (73%), diagnosis of
HCM was based on clinical judgment (i.e., LV outﬂow tract
obstruction, apical LVH, magnitude of LVH) or the evidence of a
mutation in gene analysis.
We did not use left atrial size as an exclusion criterion. Patients
with large left atrium (LA) diameters were informed about the
possibility of reduced success rate.
Paroxysmal AF and persistent AF were deﬁned according
to current guidelines [15]. Paroxysmal AF was deﬁned as
self-terminating within 7 days after onset. Persistent AF wasTable 1
Baseline parameters prior to ablation.
HCM (n = 22) Non-HCM (n = 22) p value
Male, n (%) 15 (68) 14 (64) 0.750
Age (years) 57  8 63  10 0.032
Body mass index
(kg/m2)
30  6 31  6 0.592
Persistent AF, n (%) 12 (55) 12 (55) 1.000
Coronary heart disease,
n (%)
2 (9) 2 (9) 1.000
Hypertension, n (%) 16 (73) 22 (100) 0.021
Previous stroke/TIA 0 (0) 2 (9) 0.148
Diabetes mellitus, n (%) 2 (9) 5 (23) 0.216
CHADS2 score 1 (median) 2 (median) 0.005
CHA2DS2-VASc score 1 (median) 2 (median) 0.005
LA diameter (mm) 46  8 (range 31–67) 43  6 (range 34–54) 0.183
Signiﬁcant mitral
insufﬁciency
3 (14) 0 (0) 0.073
LVEF (%) 60  7 62  7 0.286
IVSD (mm) 19  4 14  1 <0.001
ICD, n (%) 8 (36) 0 (0) 0.002
Pacemaker, n (%) 2 (9) 0 (0) 0.148
Morrow resection or
TASH
7 (32) 0 (0) 0.004
Values are mean  SD, median, or n (%).
HCM, hypertrophic cardiomyopathy; AF, atrial ﬁbrillation; LA, left atrium; TIA,
transient ischemic attack; LVEF, left ventricular ejection fraction; IVSD,
interventricular septal end diastolic dimension; ICD, implantable cardioverter-
deﬁbrillator; TASH, transcoronary ablation of septal hypertrophy.deﬁned as an AF episode either lasting longer than 7 days or
requiring drug or direct current cardioversion for termination.
All patients provided written informed consent prior to
participation.
Catheter ablation procedure
Left atrial catheter ablation was performed using a previously
described approach [16]. In brief, patients were studied under deep
propofol sedation with continuous invasive monitoring of arterial
blood pressure and oxygen saturation. Nonﬂuoroscopic 3D
catheter orientation, computed tomography image integration,
and tagging of the ablation sites were performed using Ensite
NavX, Ensite Velocity (St. Jude Medical, St. Paul, MN, USA) or
CARTO 3 (Biosense Webster, Diamond Bar, CA, USA). Transseptal
access and catheter navigation were performed with a steerable
sheath (Agilis, St. Jude Medical). If a double transseptal puncture
approach was adopted, a second long nonsteerable sheath was
used (Swartz Support Sheath SL0; St. Jude Medical), while the
transseptal puncture was performed with a BRK transseptal needle
(St. Jude Medical). After the ﬁrst transseptal puncture a bolus dose
of heparin was administered intravenously and activated clotting
time was regularly measured in order to maintain it between 300
and 400 s.
A multisensor temperature catheter was inserted in the
esophagus, with temperatures rising over 41 8C leading to
temporal interruption of lesion placement. At the posterior wall,
a starting energy delivery of 25 W was preselected, while at other
sites energy was raised up to 50 W.
In all patients circumferential left atrial ablation lines were
placed around the antrum of the ipsilateral pulmonary veins with
an irrigated tip catheter (preselected tip temperature of 48 8C, and
maximum power of 30–50 W). In case of AF induction after
pulmonary vein isolation (PVI), additional linear lesions were
added at the discretion of the operator, e.g. at the left atrial roof, the
basal posterior wall, and the mitral isthmus. Ablation of complex
fractionated electrograms was not performed.
After circumferential line placement, voltage and pace mapping
along the ablation line were used to identify and close gaps. The
isolation of all pulmonary veins with bidirectional block was
veriﬁed with a multipolar circular mapping catheter and was
deﬁned as the procedural endpoint. Table 2 shows the procedural
characteristics.
During repeat procedures, bidirectional electrical re-isolation
of pulmonary veins was the primary endpoint. Atrial bursts of
300, 250, and 200 ms were used in order to induce atrial
tachycardias. High-dose isoproterenol challenge was not admin-
istered. After complete electrical isolation of pulmonary veins,
additional linear lesions were placed in the case of macroreentry
tachycardia, after thorough activation and entrainment mapping.Table 2
Procedural parameters.
HCM (n = 22) Non-HCM (n = 22) p value
Persistent AF, n (%) 12 (55) 12 (55) 1.000
Number of interventions, n (%) 0.045
1 14 (64) 19 (86)
2 5 (23) 3 (14)
3 3 (14) 0
Duration of procedure (min) 174  56 152  44 0.179
Duration of ablation (s) 2120  1178 2575  1171 0.344
Duration of ﬂuoroscopy (min) 31  10 35  17 0.414
Additional lesions (roof line,
septal line and cavo-tricuspidal
isthmus line), n (%)
7 (32) 5 (23) 0.498
HCM, hypertrophic cardiomyopathy; AF, atrial ﬁbrillation.
Fig. 1. Kaplan–Meier curve depicts the time to ﬁrst recurrence after ﬁrst ablation.
AF, atrial ﬁbrillation; HCM, hypertrophic cardiomyopathy.
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in the left or right atrium, if a focal atrial tachycardia could be
demonstrated.
Follow-up
Seven-day Holter recordings (Lifecard CF, Delmar-Reynolds
Medical Inc., Irvine, CA, USA) were performed during 6-, 12-, and
24-month follow-up visits in our outpatient clinic. During
nonrecorded periods, the patients were advised to contact our
hospital themselves or through their family physicians in case of
any symptom recurrence. Available information from interroga-
tions of pacemakers or ICD with an atrial lead was also used for
continuous monitoring. If necessary, the patient was readmitted to
the hospital and synchronized electrical cardioversion to sinus
rhythm (SR) was performed. If available, a 12-lead electrocardio-
gram (ECG) of the episode was recorded. Documented episodes of
sustained (more than 30 s) AF or atrial ﬂutter (including
documentation from ECG, Holter recordings, and pacemaker or
ICD interrogation) after a 3-month blanking period excluded were
considered as recurrence of arrhythmia.
As standard protocol in our institution, any AAA therapy before
the ablation procedure was discontinued afterward and patients
received only titrated doses of beta-blocker. However, AAAs were
continued in some patients at the discretion of the treating
physician, e.g. in patients with recurrent arrhythmia.
In patients with symptomatic postinterventional arrhythmia
recurrences refractory to AAA treatment re-ablations were
considered after 3–6 months of follow-up.
According to current guidelines, anticoagulation was continued
in all patients based on the CHADS-VASc score, independently of
the rhythm during the follow-up [15].
Statistical analysis
Continuous variables are reported as mean  one standard
deviation and categorical variables are reported as frequencies.
Continuous variables were compared using the Student t-test, while
categorical variables were compared using the chi-square test.
Freedom from AF after last procedure was compared in both
groups by means of Mantel–Cox test and presented as Kaplan–
Meier curves. A two-tailed p-value less than 0.05 was considered
statistically signiﬁcant. Analysis was performed with SPSS v 20.0
(SPSS Inc., Chicago, IL, USA).
Results
Population
In this study, patients with HCM were younger with a greater
magnitude of LVH and a lower calculated thromboembolic risk
score. A total of 5 of 22 patients with HCM (23%) underwent
genetic testing. Genetic analysis was positive in three of
ﬁve tested patients (60%). In two patients different heterocygote
mutations were found in MYH7. In one patient a heterocygote
mutation in MYBPC3 was found. The apical form of HCM was
diagnosed in two patients (9%). HCM with left ventricular
outﬂow tract obstruction was diagnosed in eight patients (36%).
A total of seven of eight patients with left ventricular outﬂow
tract obstruction (32% in total) had undergone previous Morrow
procedure or transcoronary ablation of septal hypertrophy
(TASH). Within the HCM cohort, two patients (9%) had a
pacemaker implanted and eight patients (36%) were ICD carriers.
None of the patients with secondary hypertrophy had undergone
Morrow procedure, TASH, pacemaker, or ICD implantation.
Table 1 displays the baseline characteristics.Procedural aspects
Complete PVI as procedural endpoint was achieved in all
patients. The periprocedural parameters in terms of procedure
duration, required ablation time, and ﬂuoroscopy were similar in
both groups (Table 2). Additional lesions (roof line between both
superior pulmonary veins, septal line between the mitral annulus
and the right superior pulmonary vein, and cavo-tricuspidal
isthmus line) were performed in seven patients (32%) in the
HCM group and in ﬁve patients (23%) in the non-HCM group
(p = 0.498).
Freedom from AF and left atrial ﬂutter
Recurrences of arrhythmias after the ﬁrst ablation were
observed in 13 of 22 patients with HCM (59%) as opposed to 11
of 22 (50%) in the non-HCM group. Although the recurrence rate in
both groups was similar after a single ablation procedure
(p = 0.545), the Mantel–Cox analysis revealed that the time to
recurrence after a single ablation procedure was signiﬁcantly
shorter in the HCM group with a mean freedom from AF of 12  2
months compared to 19  2 months in the non-HCM group
(p = 0.015) (Fig. 1).
Recurrences of AF and/or atrial ﬂutter after the last ablation
occurred in 10 of 22 patients with HCM (46%) compared to 8 of
22 patients (36%) in the non-HCM group (p = 0.376). However, the
time to recurrence after multiple procedures was similar in both
groups. Recurrences after the last ablation were observed after a
mean follow-up of 12  11 months in the HCM group and after
17  7 months in the non-HCM group (p = 0.121) (Fig. 2).
To reach a comparable level of freedom from AF in patients with
HCM a higher number of repeated procedures was needed. In the
HCM group ﬁve patients (23%) were re-ablated as compared to
three patients (14%) without HCM. In three patients with HCM a
3rd procedure was required, which was not observed in the non-
HCM group (p = 0.045).
Interestingly, 8 of 13 patients (62%) with recurrences in the
HCM group after the ﬁrst procedure experienced episodes of left
atrial ﬂutter during the follow-up. After the last procedure 7 of
10 patients (70%) still had episodes of left atrial ﬂutter. Redo
procedures revealed pulmonary vein re-conduction in two of
ﬁve patients. Additional linear ablation was undertaken in
all ﬁve patients with HCM and redo procedures due to inducible
pulmonary vein independent left atrial ﬂutter.
Fig. 2. Kaplan–Meier curve depicts the time to ﬁrst recurrence after last ablation. AF,
atrial ﬁbrillation; HCM, hypertrophic cardiomyopathy.
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experienced episodes of left atrial ﬂutter after the ﬁrst procedure,
whereas recurrence of AF without evidence of left atrial ﬂutter
occurred in 8 of 11 patients (73%) (p = 0.087). After the last ablation,
left atrial ﬂutter was still detectable in three of ﬁve patients with
recurrences in the non-HCM group and only the recurrence rate
of AF decreased. In all three cases of re-ablation in non-HCM
patients a pulmonary vein re-conduction was observed and PVI
was completed. Two patients were treated with additional linear
ablation because of pulmonary vein independent left atrial ﬂutter.
AAAs were prescribed to 6 of 22 patients in the HCM group
(27%) (amiodarone in four cases and sotalol in two cases), whereas
none of the patients in the comparison group was under AAA
during follow-up (p = 0.008).
Predictors for freedom from AF
Of nine HCM patients with a LA diameter greater than 45 mm
there were only three patients (33%) without recurrent AF whereas
six patients (67%) had AF recurrence (p = 0.041). In the non-HCM
group LA size greater than 45 mm did not predict AF recurrence
(p = 0.402). Patients’ age and type of AF were no predictors for the
outcome of RFCA in our study population.
Complications
Procedure-associated complications occurred in 1 of 22
patients (5%) in the HCM group (pulmonary vein stenosis thatTable 3
Studies reporting on catheter ablation of atrial ﬁbrillation in patients with hypertroph








Liu et al. [17] Retrospective cohort 4 2 (50) 57  8 4 
Kilicaslan et al. [18] Retrospective cohort 27 19 (70) 55  10 10
Duytschaever et al. [13] Case report 2 2 (100) 47  10 1 
Gaita et al. [12] Prospective case control 26 18 (69) 58  11 6 
Bunch et al. [19] Prospective cohort 33 25 (76) 51  11 8 
Di Donna et al. [20] Retrospective cohort 61 44 (72) 54  13 12
Santangeli et al. [23] Prospective cohort 43 29 (67) 59  8 N.
Varying units have been adapted.
N.n., Nomen nominandum – not reported.was subsequently treated with balloon dilation), whereas no
complication occurred in the comparison group (p = 0.351).
Discussion
Main ﬁndings
The present study demonstrates that RFCA in the majority of
HCM patients may result in a long-term freedom from AF, although
there is frequent need for redo procedures, and antiarrhythmic
medications often cannot be discontinued.
Comparison with previous studies
Previous studies have demonstrated that RFCA for symptomatic
AF is both a feasible and safe approach in patients with HCM
[1,12,13,17–20]. Table 3 shows the main baseline, procedural and
outcome characteristics of previous studies of RFCA of AF in HCM
patients. Various factors were found predicting the outcome of
RFCA for AF in HCM patients: LA size, evidence of diastolic
dysfunction, duration of AF, type of AF, and age of patients. Patients
younger than 50 years with smaller LA, milder symptoms, and
shorter duration of AF seemed to be the best candidates for RFCA
[20]. RFCA was more successful in patients with paroxysmal AF
compared to the subgroup with permanent AF [12]. Increased LA
size was found as a risk factor for AF recurrence after RFCA in
patients with HCM [20].
In our study population, LA dimension greater than 45 mm was
also a signiﬁcant predictor for a nonfavorable outcome after RFCA
in patients with HCM. In the non-HCM group, however, LA size
greater than 45 mm did not predict AF recurrence (p = 0.402).
In contrast to previous studies that have shown the inﬂuence of
patients’ age [20] and type of AF [12] on the outcome of RFCA, in
our study population these parameters did not predict the
outcome of RFCA.
Numerous potential mechanisms may explain why patients
with HCM have higher AF recurrence rates after PVI: (1) Increased
LA size is a frequent ﬁnding in patients with HCM and secondary
hypertrophy due to impaired diastolic function and mitral
insufﬁciency. Atrial stretch shortens the effective refractory period,
increases the dispersion of the atrial effective refractory period,
and potentiates the activity of ectopic triggers [21–23]. (2) The
thickness of the left atrium exhibits a great variation between
regions within the left atrium and among different patients [24].
Atrial tissue in hearts with LVH may differ from atrial tissue in
hearts without LVH. (3) Increased prevalence of atrial ﬁbrosis may
provide a substrate for slow conduction and intra-atrial reentry
and it may therefore increase the susceptibility to AF by increased
vulnerability to triggers [25]. (4) Myocardial ischemia and
autonomic dysfunction, both of which have been documented in


















(100) 4 (100) 6  3 1 (25) 1 (25) N.n. 4 (100)
0% 14 (52) 11  8 7 (26) 6 (22) 0% 19 (70)
(50) 1 (50) 11  1 0 2 (100) N.n. 2 (100)
(23) 13 (50) 19  10 5 (19) 6 (23) 0 (0) 14 (56)
(24) 21 (64) 18  14 13 (39) 4 (13) 3 (9) 25 (75)
 (20) 35 (56) 29  16 32 (52) 31 (51) 0 (0) 41 (67)
n. 12 (28) 42  6 22 (51) 0 (0) 0 (0) 21 (49)
A. Mu¨ssigbrodt et al. / Journal of Cardiology 65 (2015) 474–478478Conclusion
In conclusion, RFCA was successful in restoring long-term SR in
the majority of patients with LVH due to HCM and due to
secondary etiology. However, patients with HCM needed more
RFCA procedures and frequently additional AAA therapy in order to
maintain SR. Left atrial ﬂutter was found more frequently in
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